- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
-
- Taniguchi Gentaro
- Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Japan
-
- Matsushima Shouji
- Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Japan
-
- Fujino Takeo
- Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Japan Department of Advanced Cardiopulmonary Failure, Graduate School of Medical Sciences, Kyushu University, Japan
-
- Hashimoto Toru
- Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Japan
-
- Shinohara Keisuke
- Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Japan
-
- Kisanuki Hiroshi
- Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Japan
-
- Misumi Kayo
- Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Japan
-
- Katsuki Shunsuke
- Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Japan
-
- Shiose Akira
- Department of Cardiovascular Surgery, Graduate School of Medical Sciences, Kyushu University, Japan
-
- Abe Kohtaro
- Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Japan
Search this article
Description
<p>A 67-year-old man on intense immunosuppressive therapy after heart transplantation for end-stage hypertrophic cardiomyopathy 7 years ago developed severe dyspnea and was admitted to our hospital. His serum SARS-CoV-2 antigen test was positive, and he was diagnosed with COVID-19-related pneumonia. He was started on ventilatory management for severe respiratory failure and remdesivir for COVID-19, with careful adjustment of immunosuppressive drugs. However, unexpectedly prolonged muscle weakness necessitated transfer to a rehabilitation facility. Although the COVID-19 pandemic has subsided, it is still considered a risk in post-transplant cases. Infection control is considered critical in heart transplant recipients, especially in those receiving intensified immunosuppressive drugs. </p>
Journal
-
- Internal Medicine
-
Internal Medicine advpub (0), 2025
The Japanese Society of Internal Medicine
